Guard Therapeutics International AB Asset Resilience Ratio

Latest as of September 2025: 98.42%

Guard Therapeutics International AB asset resilience ratio. Guard Therapeutics International AB (GUARD) has an Asset Resilience Ratio of 98.42% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Guard Therapeutics International AB to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr69.76 Million
≈ $7.51 Million USD Cash + Short-term Investments

Total Assets

Skr70.88 Million
≈ $7.63 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Guard Therapeutics International AB (2016–2023)

Asset resilience ratio of Guard Therapeutics International AB from 2016 to 2023. This chart shows how Guard Therapeutics International AB's Asset Resilience Ratio has changed over time. Read Guard Therapeutics International AB total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Guard Therapeutics International AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GUARD total asset value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr69.76 Million 98.42%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr69.76 Million 98.42%

Asset Resilience Insights

  • Very High Liquidity: Guard Therapeutics International AB maintains exceptional liquid asset reserves at 98.42% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Guard Therapeutics International AB Industry Peers by Asset Resilience Ratio

Compare Guard Therapeutics International AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

Guard Therapeutics International AB Asset Resilience Ratio by Year (2016–2023)

Guard Therapeutics International AB asset resilience ratio by year from 2016 to 2023. The table below shows the annual Asset Resilience Ratio data for Guard Therapeutics International AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 98.26% Skr83.74 Million
≈ $9.01 Million
Skr85.23 Million
≈ $9.17 Million
-0.96pp
2022-12-31 99.21% Skr201.01 Million
≈ $21.63 Million
Skr202.60 Million
≈ $21.80 Million
+0.17pp
2021-12-31 99.04% Skr188.60 Million
≈ $20.30 Million
Skr190.44 Million
≈ $20.49 Million
+0.33pp
2020-12-31 98.71% Skr90.04 Million
≈ $9.69 Million
Skr91.22 Million
≈ $9.82 Million
+14.21pp
2019-12-31 84.50% Skr53.84 Million
≈ $5.79 Million
Skr63.71 Million
≈ $6.86 Million
+33.32pp
2018-12-31 51.18% Skr13.96 Million
≈ $1.50 Million
Skr27.28 Million
≈ $2.94 Million
+33.74pp
2017-12-31 17.44% Skr7.61 Million
≈ $819.17K
Skr43.65 Million
≈ $4.70 Million
+0.94pp
2016-12-31 16.50% Skr7.01 Million
≈ $754.28K
Skr42.47 Million
≈ $4.57 Million
--
pp = percentage points

About Guard Therapeutics International AB

ST:GUARD Sweden Biotechnology
Market Cap
$3.19 Million
Skr29.61 Million SEK
Market Cap Rank
#29367 Global
#662 in Sweden
Share Price
Skr1.47
Change (1 day)
+1.24%
52-Week Range
Skr0.95 - Skr2.35
All Time High
Skr3260.75
About

Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. Its pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to tre… Read more